8-K

                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): July 6, 2005

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))




Item 8.01  Other Events

On July 6, 2005, Techne Corporation issued a press release announcing
that its R&D Systems subsidiary had acquired Fortron Bio Science, Inc. and
BiosPacific, Inc., both privately held companies. A copy of the press
release is attached hereto as exhibit 99.1


Item 9.01 Financial Statements and Exhibits

     (c) Exhibits

        99.1   Press Release dated July 6, 2005.







                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: July 7, 2005                    TECHNE CORPORATION
                                      By: /s/ Thomas E. Oland
                                      ---------------------------
                                      Name: Thomas E. Oland
                                      Title: President and Chief
                                        Executive Officer



                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------
       99.1     Press release of Techne Corporation dated July 6, 2005.

EX-99.1

               TECHNE CORPORATION ANNOUNCES ACQUISITIONS

Minneapolis/July 6, 2005/--Techne Corporation (NASDAQ: TECH) announced today
that its R&D Systems subsidiary has acquired Fortron Bio Science, Inc., a
developer and manufacturer of monoclonal and polyclonal antibodies, antigens
and other biological reagents. R&D Systems simultaneously acquired
BiosPacific, Inc., a worldwide supplier of biologics to manufacturers of in
vitro diagnostic systems (IVDs) and immunodiagnostic kits.  These kits are
used globally in both clinical laboratory and point-of-care testing for
evidence of cardiovascular disease, cancer, infectious diseases, endocrine,
thryroid and fertility disorders, and drugs of abuse.  BiosPacific is the
primary distribution arm of Fortron.  R&D Systems is a leading developer and
manufacturer purified cytokines (proteins), antibodies and assay kits which
are sold to biomedical researchers and clinical research laboratories.

Fortron and BiosPacific had shared a unique strategic relationship since 1992
that combines Fortron's development and manufacturing excellence with
BiosPacific's marketing and sales expertise.  This partnership has been vital
in assisting diagnostic companies to bring innovative assays to the market.
The acquisitions will enhance R&D Systems' ability to serve the diagnostics
industry.

All of the shares of privately-held Fortron and substantially all of the
assets of privately-held BiosPacific were acquired for an aggregate $20.0
million in cash.  R&D Systems also assumed certain liabilities of
BiosPacific, and incurred transaction expenses.

Fortron and BiosPacific generated combined revenues of approximately $8.7
million in calendar 2004.  The acquisitions are expected to be slightly
accretive to Techne's earnings per share in its fiscal year ending June 30,
2006.  However, the purchase price allocation of these acquisitions has not
been completed.  We are therefore not able to predict the impact of the
intangible amortization or a potential charge for in-process research and
development expense associated with the acquisitions, if any, on estimated
fiscal year 2006 earnings per share.

Tom Oland, President and CEO of Techne Corporation said, "I strongly believe
there is potential synergy associated with these acquisitions and our
business.  Fortron and BiosPacific have earned a reputation as suppliers of
high quality reagents to manufacturers of in-vitro diagnostic kits and have
established themselves as a key vendor to many of the major diagnostic
companies.  R&D Systems has focused its business on the research markets
where it has earned a reputation for high quality products.  With these
acquisitions we will be able to expand into the diagnostic market by offering
some of our research reagents that may have future diagnostic application
and/or by using our expertise to develop products specifically for the
diagnostic markets."

Fortron founder and President Dick Wicks will remain available to the Company
as an advisor regarding continuing product development.  Sandy Koshkin,
BiosPacifics' founder, CEO and President will remain active in promoting and
enhancing relationships with diagnostic manufacturers.

Statements in this earnings release and elsewhere, which look forward in time
involve risks and uncertainties which may affect the actual results of
operations. The following important factors, among others, have affected and,
in the future, could affect the Company's actual results: the introduction
and acceptance of new biotechnology and hematology products, the levels and
particular directions of research by the Company's customers, the impact of
the growing number of producers of biotechnology research products and
related price competition, the retention of hematology OEM and proficiency
survey business, the impact of currency exchange rate fluctuations, and the
costs and results of research and product development efforts of the Company
and of companies in which the Company has invested or with which it has
formed strategic relationships. For additional information concerning such
factors, see the Company's annual report on Form 10-K and quarterly reports
on Form 10-Q as filed with the Securities and Exchange Commission.

                      * * * * * * * * * * * * * *

Techne Corporation has two operating subsidiaries: Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England. R&D Systems is a specialty
manufacturer of biological products and R&D Europe is a distributor of
biotechnology products.

Contact:
Greg Melsen, Chief Financial Officer
Kathy Backes, Controller
(612) 379-8854